"Bucindolol offers physicians a tremendous advantage to predict response," said William Abraham, M.D., Director of Cardiovascular Medicine at the Ohio State University Medical Center. "This is vitally important since the annual mortality rate for heart failure patients can be as high as 20 percent. With these patients, we have no time to spare."
Michael Bristow, M.D., Chairman and Chief Science and Medical Officer of ARCA biopharma, said, "While currently available beta blockers are a mainstay in medicine, it is difficult for physicians to predict which patients will respond to which therapy. Bucindolol interacts with certain polymorphisms of adrenergic receptors that help regulate cardiac function, allowing us to predict patient clinical response using a simple genetic test. The time is coming when we can realize the benefits of personalized medicine in cardiovascular disease."
About Beta Blockers
The use of beta blockers is the standard of care in patients with heart
failure and left ventricular dysfunction, according to clinical practice
guidelines of the Heart Failure Society of America (HFSA), the American
Heart Association and the American College of Cardiology. HFSA guidelines
state: "Beta-blocker therapy remains a major advance in the treatment of
patients with LV systolic dysfunction. Along with ACE inhibitors, this
class of drug is now established as routine therapy in pati
|SOURCE ARCA biopharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved